NR4A1 and breast cancer: Although, a study declared that the hormone receptor-positive BC possessed a similar rate of dMMR as TNBC patients (17% vs. 20%), which was also noted, response rates from PD-1 inhibitors (e.g., avelumab, an anti-PD-L1 antibody) was obviously lower than that of TNBC (14, 30).